• In February 2026, BeOne Medicines AG reported past fourth-quarter 2025 revenue of US$1.50 billion and net income of US$66.5 million, bringing full-year revenue to US$5.34 billion and net income to US$286.93 million, alongside a move from a loss per share to positive earnings per share.
• The company also issued 2026 guidance pointing to total revenue of US$6.2–US$6.4 billion and GAAP operating income of US$700–US$800 million, marking a shift to meaningful profitability.
• Against this backdrop of stronger profitability and higher 2026 operating income guidance, we’ll explore how the latest results influence BeOne’s investment narrative.

We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

BeOne Medicines Investment Narrative Recap

To own BeOne Medicines, you need to believe its oncology portfolio, still anchored by BRUKINSA and key solid tumor assets, can justify a high earnings multiple despite concentration and competitive pressure. The latest move to US$286.93 million in 2025 net income and guided GAAP operating income of US$700–US$800 million for 2026 reinforces the near term profitability catalyst, but does little to reduce the core risks around product reliance, pricing pressure and execution on late stage trials.

The most relevant recent announcement here is the 2026 guidance for total revenue of US$6.2–US$6.4 billion and GAAP operating income of US$700–US$800 million, which frames how quickly BeOne aims to scale profitability. For investors focused on near term catalysts, this guidance connects directly to questions about whether BRUKINSA and the broader portfolio can support that earnings step up without overextending R&D and commercial spending in a competitive oncology market.

Yet beneath the strong 2025 results, investors should also be aware of how concentrated BRUKINSA exposure and intensifying oncology competition could...

BeOne Medicines’ narrative projects $7.6 billion revenue and $1.3 billion earnings by 2028.

Uncover how BeOne Medicines' forecasts yield a $404.19 fair value, a 42% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming roughly US$5.3 billion in revenue and only US$191.7 million in earnings by 2028, which is far more cautious than the recent results, so it is worth asking how their more pessimistic view on BRUKINSA reliance and pricing pressure might shift in light of BeOne’s latest profitability step up.

Explore 6 other fair value estimates on BeOne Medicines - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your BeOne Medicines research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free BeOne Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BeOne Medicines' overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Invest in the nuclear renaissance through our list of 86 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.